Takeda Pharmaceutical Co Ltd ADR (TAK)vsUnited Therapeutics Corporation (UTHR)
TAK
Takeda Pharmaceutical Co Ltd ADR
$16.46
-1.08%
HEALTHCARE · Cap: $52.57B
UTHR
United Therapeutics Corporation
$564.94
-0.74%
HEALTHCARE · Cap: $24.16B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 140747% more annual revenue ($4.46T vs $3.17B). UTHR leads profitability with a 40.6% profit margin vs 2.5%. TAK appears more attractively valued with a PEG of 0.33. TAK earns a higher WallStSmart Score of 60/100 (C).
TAK
Buy60
out of 100
Grade: C
UTHR
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for TAK.
Margin of Safety
+11.2%
Fair Value
$535.96
Current Price
$564.94
$28.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Generating 317.5B in free cash flow
Large-cap with strong market position
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Areas to Watch
4.2% revenue growth
ROE of 1.5% — below average capital efficiency
2.5% margin — thin
Premium valuation, high expectations priced in
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.33 suggests the stock is reasonably priced for its growth.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 75.6x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
TAK profiles as a value stock while UTHR is a declining play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.59 — expect wider price swings.
TAK is growing revenue faster at 4.2% — sustainability is the question.
TAK generates stronger free cash flow (317.5B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (60/100 vs 57/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?